Chicago, IL (PRWEB) October 8, 2007
Women diagnosed with HER-2 positive Stage III or Stage IV breast cancer are eligible to participate in a clinical trial investigating early detection of brain metastases from advanced breast cancer through education and screening.
The trial will take place on Friday, October 26th, from 1 to 9 p.m. and Saturday, October 27th, from 8 a.m. to 5 p.m. The location is the Neurologic and Orthopedic Institute of Chicago, 4501 N. Winchester, Chicago: http://www.neuro-ortho.org. The brain MRI is free of charge to the patient.
HER2 is a breast cancer that tests positive for a protein called human epidermal growth factor receptor-2 (HER2), which promotes the growth of cancer cells. Studies have shown that as many as 30 percent of patients with breast cancer have it spread to the brain. As part of the screening protocol, participants will undergo a MRI of the brain. The cost of the MRI is covered by the clinical trial.
Patients who qualify must have an initial primary diagnosis of high risk and/or HER-2 positive breast cancer. They must be at least 18 years and should not participate if they are pregnant.
The Chicago Institute of Neurosurgery and Neuroresearch (CINN) Medical Group will use information from the screening to determine the potential benefit(s) of screening for brain metastases in patients with advanced breast cancer. More information about the study's Principal Investigator, Dr. Gail Rosseau, can be found here: http://www.neuro-ortho.org/clinical-trials/brain-screening.htm.
The study selection and enrollment criteria stipulate that women must be within three to twenty-four months of first metastases of Stage IV diagnosis or within 12 to 24 months of initial diagnosis of HER-2 positive Stage III disease. They must sign a written consent form approved by the CINN Institutional Review Board (IRB).
The exclusion criteria stipulate that patients with a prior diagnosis of brain metastases or who are unable to be safely exposed to MRIs cannot participate. Most common exclusions include, but are not limited to, pacemakers, implanted defibrillators, neurostimulators, aneurysm clips, cochlear devices, or any other institution contraindications. Additionally, women who are pregnant are also ineligible.
The Neurologic & Orthopedic Institute of Chicago is the country's first freestanding acute care hospital dedicated exclusively to neuroscience and orthopedic services. It utilizes breakthrough technology and minimally invasive techniques as well as advanced procedures for neurosurgery, orthopedics, pain management, neuro-oncology, sports medicine, and rehabilitation.